Trexquant Investment’s Alexion Pharmaceuticals ALXN Stock Holding History

Trexquant Investment’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-47,881	Closed	-$4.69M	–	1346
2019 Q3	$4.69M	Buy	+47,881	New	+$5.4M	0.41%	62
2019 Q1	–	Sell	-63,149	Closed	-$6.15M	–	1427
2018 Q4	$6.15M	Buy	+63,149	New	+$7.46M	0.38%	42
2018 Q3	–	Sell	-6,638	Closed	-$824K	–	1287
2018 Q2	$824K	Sell	6,638 -38,180	-85%	-$4.46M	0.06%	417
2018 Q1	$5M	Buy	+44,818	New	+$5.36M	0.35%	48
2017 Q2	–	Sell	-11,000	Closed	-$1.33M	–	1303
2017 Q1	$1.33M	Buy	+11,000	New	+$1.42M	0.17%	153
2016 Q4	–	Sell	-4,800	Closed	-$588K	–	1202
2016 Q3	$588K	Sell	4,800 -14,700	-75%	-$1.89M	0.13%	257
2016 Q2	$2.28M	Buy	+19,500	New	+$2.77M	0.3%	70

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Trexquant Investment's ALXN Position: Q4 2019 in Review

Trexquant Investment sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 47,881 shares — an estimated $4.69M sold.

Trexquant Investment first reported a position in ALXN in Q2 2016 and held it in 7 quarters. The position peaked at $6.15M in Q4 2018. 669 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

Trexquant Investment reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Trexquant Investment sold 47,881 Alexion Pharmaceuticals shares in Q4 2019, an estimated $4.69M.
Trexquant Investment first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 7 quarters.
Trexquant Investment's Alexion Pharmaceuticals position peaked at $6.15M in Q4 2018.
669 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Trexquant Investment's 13F filing for Q4 2019, filed 12 Feb 2020.